Leonard Zehr, Author at BioTuesdays

Feature

Contextual Genomics detecting genetic mutations in cancer

By Len Zehr Closely-held Contextual Genomics is giving oncologists a leg up to enhance cancer care with its new Find-It molecular test to detect genetic mutations in cancer patients. “We deliver solutions through our...

August 15, 2017

Feature

CKD patients opt to stay on Dimerix drug after trial

By Len Zehr Forty-five per cent of patients in Dimerix’s (ASX:DXB) successful Phase 2a trial in chronic kidney disease (CKD), on advice from their physician, applied for and were granted access to remain on DMX-200...

August 8, 2017

Feature

Scientus enters commercialization stage of growth, readies launch of lead product

By Len Zehr Closely-held Scientus Pharma expects to launch its first cannabis soft gel capsules for the treatment of neuropathic pain at the end of the year, to be followed in early 2018 with a soft gel for epilepsy and...

August 1, 2017

Feature

Appili readies antibiotic bridging study

By Len Zehr Closely-held Appili Therapeutics plans to begin late in the current quarter a Phase 1 bridging, or bioequivalence, study of its lead anti-infective, ATI-1501, a reformulated, taste-masked liquid suspension...

July 25, 2017

Feature

PureTech targeting dysfunctions in brain, gut, immune system

By Len Zehr With eight clinical-stage studies underway, including two pivotal trials expected to readout later this year, PureTech Health (LSE:PRTC) is taking a novel approach to drug development, targeting serious...

July 18, 2017

Feature

In conversation with John Gannon of TempTraq

By Len Zehr As president and CEO of closely-held Blue Spark Technologies and co-inventor of its newest product, TempTraq, John Gannon’s career has stretched from the aerospace industry to Wall Street, culminating in...

July 11, 2017

Developments

IntelGenx files final prospectus for debenture offering

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has filed a final short form prospectus in connection with its previously announced offering of a minimum of $5-million and a maximum of $10-million principal amount of 8%...

June 30, 2017

Developments

IntelGenx gets U.S. patent allowance for oral films

IntelGenx (OTCQX:IGXT; TSXV:IGX;) has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application entitled, “Solid oral film dosage forms and methods for making same.” The platform...

June 27, 2017

Feature

Klox focused on oral care launch, partner for wound care

By Len Zehr With franchises in dermatology, wound care and oral health, closely-held Klox Technologies has three near-term milestones this year: launching its oral care business with Colgate Palmolive; expanding the...

June 27, 2017

Feature

Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

By Len Zehr As president and CEO of newly formed Canopy Health Innovations, a spin off of Canopy Group (TSX:WEED), a world leading diversified cannabis company, Marc Wayne is a pioneer of the medical cannabis sector. He...

June 20, 2017

Author - Leonard Zehr

Contextual Genomics detecting genetic mutations in cancer

CKD patients opt to stay on Dimerix drug after trial

Scientus enters commercialization stage of growth, readies launch of lead product

Appili readies antibiotic bridging study

PureTech targeting dysfunctions in brain, gut, immune system

In conversation with John Gannon of TempTraq

IntelGenx files final prospectus for debenture offering

IntelGenx gets U.S. patent allowance for oral films

Klox focused on oral care launch, partner for wound care

Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

General

More